Sector News

Roche buys U.S.-based Kapa Biosystems

August 20, 2015
Life sciences
(MarketWatch) – Roche Holding AG (ROG.VX) Wednesday said it has bought a U.S. gene-technology company, the latest acquisition in the area by the Swiss pharmaceutical company.
 
Basel-based Roche said it will buy Kapa Biosystems Inc., based in Wilmington, Mass., for an undisclosed sum. The closely held U.S. company has been working on ways to accelerate research into genomes, the complete set of DNA with within a single cell.
 
Roche is interested in the area because it leads to a better understanding of the genetic roots of diseases by identifying genetic mutations. Genome research can affect the future ability to diagnose, monitor and treat cancer and other conditions.
 
Kapa’s protein-engineering technology allows for the generation and screening of large numbers of enzyme variants, Roche said. Tailored enzymes with improved performance for specific applications can be rapidly selected, speeding up product development time lines, the company added.
 
Last week, Roche said it was buying GeneWEAVE BioSciences, a California-based developer of clinical microbiology with diagnostics solutions, for an initial $190 million.
 

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach